Pemphigus Vulgaris Overview
Pemphigus Vulgaris is a common manifestation of arterial stenosis of the lower and/or upper extremities that reduces arterial flow. It is well known that Pemphigus Vulgaris is associated with elevated morbidity and mortality with cardiovascular disease. In Pemphigus Vulgaris, the legs or arms, usually the legs, do not receive enough blood flow to keep up with the demand, which may cause leg pain when walking (claudication) and other symptoms. Many people with Pemphigus Vulgaris have no symptoms. The most common symptom of lower-extremity Pemphigus Vulgaris is painful muscle cramping in the hips, thighs, or calves when walking, climbing stairs, or exercising. However, those who develop a painful ache in their legs when they walk usually disappear after a few minutes of rest. The medical term for this is “intermittent claudication”. The symptoms of Pemphigus Vulgaris often develop slowly over time. If your symptoms develop quickly or get suddenly worse, it could be a sign of a serious problem requiring immediate treatment.
Pemphigus Vulgaris Epidemiology Insights
In 2022, the market size of Pemphigus Vulgaris was highest in the US among the 7MM accounting for approximately USD 4 billion, and lowest in Spain with USD 130 million which is further expected to increase by 2032.
Gender-specific diagnosed prevalent cases of Pemphigus Vulgaris were higher in females (9 million cases) as compared to males (8 million) in 2022 in the 7MM.
According to DelveInsight estimates, the US accounted for approximately 9 million cases, which was the highest diagnosed prevalent cases of Pemphigus Vulgaris , followed by EU4 and the UK with 5 million cases, and Japan with 2 million cases in 2022. These cases are expected to increase in the US, EU4, the UK, and Japan by 2032
Among the European countries, Germany had the highest diagnosed prevalent population of Pemphigus Vulgaris (approximately 2 million cases), followed by Italy (approximately 1 million cases) in 2022. On the other hand, Spain (0.7 million cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.
Pemphigus Vulgaris has been identified as a male-dominant disease; however, in our analysis, the number of women suffering was higher than males. In 2022, 49% of cases of Pemphigus Vulgaris were in males, while 51% of cases were in Females in the 7MM.
Click here to learn more about the Pemphigus Vulgaris Market Landscape
The Report Covers the Pemphigus Vulgaris Epidemiology Segmented by:
Total Pemphigus Vulgaris prevalent cases
Total Pemphigus Vulgaris type-specific prevalent cases
Total Pemphigus Vulgaris diagnosed cases
Total Pemphigus Vulgaris treatable cases
Pemphigus Vulgaris Market Outlook
The overall medical treatment for Pemphigus Vulgaris is comprehensive and involves lowering cholesterol, antiplatelet therapy, anticoagulation, peripheral vasodilators, blood pressure control, exercise therapy, and quitting smoking. Numerous medications are available for managing claudication symptoms, secondary prevention of cardiovascular problems, and limb salvage therapy. Lifestyle change, medication management, endovascular therapies, and surgical interventions are different treatment options. Following this regime can lessen atherosclerosis-related systemic problems like stroke, myocardial infarction, and limb-related complications, including critical limb ischemia and amputation. Pemphigus Vulgaris is undertreated compared to coronary artery disease. The current treatment strategies include endovascular revascularization, surgical revascularization, and primary amputation, and endovascular revascularization is a fundamental strategy to limb preservation. Other than surgical approaches, therapeutic angiogenesis can be achieved by gene and cell therapy. Collategene (HGF plasmid) is the only gene therapy that received approval in Japan. Apart from this, many cell therapies are under development.
Key Companies Working in the Pemphigus Vulgaris Market
Ixaka Ltd (formerly Rexgenero)
Hemostemix Inc
Lisata Therapeutics/ Caladrius Biosciences
Reven Pharmaceuticals, Inc
Helixmith Co., Ltd
And many others
Pemphigus Vulgaris Therapies Covered and Analyzed in the Report
ACP-01
Rivaroxaban
Ticagrelor
Clopidogrel
Vonapanitase
And many others
Learn more about the Key Companies and Emerging Therapies in the Pemphigus Vulgaris Market
Table of Contents
Key Insights
Pemphigus Vulgaris Introduction
Executive Summary of Pemphigus Vulgaris
Disease Background and Overview
Epidemiology and patient population
Pemphigus Vulgaris Emerging Therapies
Pemphigus Vulgaris Market Outlook
Pemphigus Vulgaris Market Access and Reimbursement of Therapies
Pemphigus Vulgaris Market Drivers
Pemphigus Vulgaris Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Pemphigus Vulgaris Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services